Velocardiofacial Syndrome

Child and Adolescent Psychiatric Clinics of North America

Volumn 16, Issue 3, 2007, Pages 677-693

  Gothelf, Doron ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; FLUOXETINE; METHYLPHENIDATE; METIROSINE; MOOD STABILIZER; NEUROLEPTIC AGENT; VALPROIC ACID;

ABDOMINAL DISCOMFORT; ABNORMAL BEHAVIOR; ADOLESCENCE; ADULTHOOD; APPETITE; COGNITIVE DEFECT; DEPRESSION; DRUG WITHDRAWAL; EVALUATION; GENETIC RISK; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HYPOTENSION; IRRITABILITY; LOW DRUG DOSE; MELANCHOLIA; MENTAL DISEASE; ONSET AGE; PATHOPHYSIOLOGY; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; STOMACH PAIN; VELOCARDIOFACIAL SYNDROME;

ABNORMALITIES, MULTIPLE; ADOLESCENT; CHILD; DIGEORGE SYNDROME; HUMANS; LEARNING DISORDERS; PREVALENCE;

EID: 34249941507     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2007.03.005     Document Type: Review

References (87)

1. Kirkpatrick Jr. J.A., and DiGeorge A.M. Congenital absence of the thymus. Am J Roentgenol Radium Ther Nucl Med 103 (1968) 32-37
2. Shprintzen R.J., Goldberg R.B., Lewin M.L., et al. A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome. Cleft Palate J 15 (1978) 56-62
3. Carey A.H., Kelly D., Halford S., et al. Molecular genetic study of the frequency of monosomy 22q11 in DiGeorge syndrome. Am J Hum Genet 51 (1992) 964-970
4. Driscoll D.A., Budarf M.L., and Emanuel B.S. A genetic etiology for DiGeorge syndrome: consistent deletions and microdeletions of 22q11. Am J Hum Genet 50 (1992) 924-933
5. Driscoll D.A., Spinner N.B., Budarf M.L., et al. Deletions and microdeletions of 22q11.2 in velo-cardio-facial syndrome. Am J Med Genet 44 (1992) 261-268
6. Driscoll D.A., Salvin J., Sellinger B., et al. Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: implications for genetic counselling and prenatal diagnosis. J Med Genet 30 (1993) 813-817
7. Botto L.D., May K., Fernhoff P.M., et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112 (2003) 101-107
8. Marino B., Mileto F., Digilio M.C., et al. Congenital cardivascular disease and velo-cardio-facial syndrome. In: Murphy K.C., and Scambler P.J. (Eds). Velo-cardio-facial syndrome: a model for understanding microdeletion disorders (2005), Cambridge University Press, Cambridge (MA) 47-82
9. Kirscher R.E. Palatal anomalies and velopharyngeal dysfunction associated with velo-cardio-facial syndrome. Velo-cardio-facial syndrome: a model for understanding microdeletion disorders (2005), Cambridge University Press, Cambridge (MA) 83-104
10. Murphy K.C., Jones L.A., and Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56 (1999) 940-945
11. Arinami T., Ohtsuki T., Takase K., et al. Screening for 22q11 deletions in a schizophrenia population. Schizophr Res 52 (2001) 167-170
12. Karayiorgou M., Morris M.A., Morrow B., et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 92 (1995) 7612-7616
13. Sporn A., Addington A., Reiss A.L., et al. 22q11 deletion syndrome in childhood onset schizophrenia: an update. Mol Psychiatry 9 (2004) 225-226
14. Bassett A.S., Hodgkinson K., Chow E.W., et al. 22q11 deletion syndrome in adults with schizophrenia. Am J Med Genet 81 (1998) 328-337
15. Gothelf D., Frisch A., Munitz H., et al. Velocardiofacial manifestations and microdeletions in schizophrenic inpatients. Am J Med Genet 72 (1997) 455-461
16. Bastain T.M., Lewczyk C.M., Sharp W.S., et al. Cytogenetic abnormalities in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 41 (2002) 806-810
17. Shprintzen R.J., and Golding-Kushner K.J. Evaluation of velopharyngeal insufficiency. Otolaryngol Clin North Am 22 (1989) 519-536
18. Morrow B., Goldberg R., Carlson C., et al. Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. Am J Hum Genet 56 (1995) 1391-1403
19. McDonald-McGinn D.M., Tonnesen M.K., Laufer-Cahana A., et al. Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net!. Genet Med 3 (2001) 23-29
20. Ryan A.K., Goodship J.A., Wilson D.I., et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet 34 (1997) 798-804
21. Prescott K., Ivins S., Hubank M., et al. Microarray analysis of the Df1 mouse model of the 22q11 deletion syndrome. Hum Genet 116 (2005) 486-496
22. Funke B., Pandita R.K., and Morrow B.E. Isolation and characterization of a novel gene containing WD40 repeats from the region deleted in velo-cardio-facial/DiGeorge syndrome on chromosome 22q11. Genomics 73 (2001) 264-271
23. McDermid H.E., and Morrow B.E. Genomic disorders on 22q11. Am J Hum Genet 70 (2002) 1077-1088
24. Paylor R., Glaser B., Mupo A., et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci U S A 103 (2006) 7729-7734
25. Shprintzen R.J. Velo-cardio-facial syndrome: a distinct behavioral phenotype. Ment Retard Dev Disabil Res Rev 6 (2000) 142-147
26. Arnold P.D., Siegel-Bartelt J., Cytrynbaum C., et al. Velo-cardio-facial syndrome: implications of microdeletion 22q11 for schizophrenia and mood disorders. Am J Med Genet 105 (2001) 354-362
27. Feinstein C., Eliez S., Blasey C., et al. Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: usefulness as phenotypic indicators of schizophrenia risk. Biol Psychiatry 51 (2002) 312-318
28. Fine S.E., Weissman A., Gerdes M., et al. Autism spectrum disorders and symptoms in children with molecularly confirmed 22q11.2 deletion syndrome. J Autism Dev Disord 35 (2005) 461-470
29. Gothelf D., Gruber R., Presburger G., et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 64 (2003) 1163-1169
30. Gothelf D., Presburger G., Zohar A.H., et al. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am J Med Genet Neuropsychiatr Genet 126 (2004) 99-105
31. Papolos D.F., Faedda G.L., Veit S., et al. Bipolar spectrum disorders in patients diagnosed with velo-cardio- facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?. Am J Psychiatry 153 (1996) 1541-1547
32. Prinzie P., Swillen A., Vogels A., et al. Personality profiles of youngsters with velo-cardio-facial syndrome. Genet Couns 13 (2002) 265-280
33. Swillen A., Devriendt K., Ghesquiere P., et al. Children with a 22q11 deletion versus children with a speech-language impairment and learning disability: behavior during primary school age. Genet Couns 12 (2001) 309-317
34. Baker K.D., and Skuse D.H. Adolescents and young adults with 22q11 deletion syndrome: psychopathology in an at-risk group. Br J Psychiatry 186 (2005) 115-120
35. Antshel K.M., Fremont W., Roizen N.J., et al. ADHD, major depressive disorder, and simple phobias are prevalent psychiatric conditions in youth with velocardiofacial syndrome. J Am Acad Child Adolesc Psychiatry 45 (2006) 596-603
36. Debbane M., Glaser B., Gex-Fabry M., et al. Temporal perception in velo-cardio-facial syndrome. Neuropsychologia 43 (2005) 1754-1762
37. Dykens E.M., Leckman J.F., and Cassidy S.B. Obsessions and compulsions in Prader-Willi syndrome. J Child Psychol Psychiatry 37 (1996) 995-1002
38. Mervis C.B., and Klein-Tasman B.P. Williams syndrome: cognition, personality, and adaptive behavior. Ment Retard Dev Disabil Res Rev 6 (2000) 148-158
39. Antshel KM, Aneja A, Strunge L, et al. Autistic spectrum disorders in velo-cardio facial syndrome (22q11.2 deletion). J Autism Dev Disord 2007, in press.
40. Niklasson L., Rasmussen P., Oskarsdottir S., et al. Neuropsychiatric disorders in the 22q11 deletion syndrome. Genet Med 3 (2001) 79-84
41. Vorstman J.A., Morcus M.E., Duijff S.N., et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry 45 (2006) 1104-1113
42. Gothelf D, Feinstein C, Thompson T, et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry 2007;164(4):663-9.
43. Bassett A.S., Chow E.W., AbdelMalik P., et al. The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry 160 (2003) 1580-1586
44. Usiskin S.I., Nicolson R., Krasnewich D.M., et al. Velocardiofacial syndrome in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 38 (1999) 1536-1543
45. Turner T.H. Schizophrenia and mental handicap: an historical review, with implications for further research. Psychol Med 19 (1989) 301-314
46. Murphy K.C. Schizophrenia and velo-cardio-facial syndrome. Lancet 359 (2002) 426-430
47. Swillen A., Devriendt K., Legius E., et al. Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS. J Med Genet 34 (1997) 453-458
48. Simon T.J., Bish J.P., Bearden C.E., et al. A multilevel analysis of cognitive dysfunction and psychopathology associated with chromosome 22q11.2 deletion syndrome in children. Dev Psychopathol 17 (2005) 753-784
49. Campbell L.E., and Swillen A. The cognitive spectrum in velo-cardio-facial syndrome. In: Velo-cardio-facial syndrome: a model for understanding microdeletion disorders (2005), Cambridge University Press, Cambridge (MA) p. 147-64
50. Henry J.C., van Amelsvoort T., Morris R.G., et al. An investigation of the neuropsychological profile in adults with velo-cardio-facial syndrome (VCFS). Neuropsychologia 40 (2002) 471-478
51. Gothelf D., Eliez S., Thompson T., et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 8 (2005) 1500-1502
52. Sobin C., Kiley-Brabeck K., Daniels S., et al. Networks of attention in children with the 22q11 deletion syndrome. Dev Neuropsychol 26 (2004) 611-626
53. Woodin M., Wang P.P., Aleman D., et al. Neuropsychological profile of children and adolescents with the 22q11.2 microdeletion. Genet Med 3 (2001) 34-39
54. Kates W.R., Burnette C.P., Bessette B.A., et al. Frontal and caudate alterations in velocardiofacial syndrome (deletion at chromosome 22q11.2). J Child Neurol 19 (2004) 337-342
55. Eliez S., Barnea-Goraly N., Schmitt J.E., et al. Increased basal ganglia volumes in velo-cardio-facial syndrome (deletion 22q11.2). Biol Psychiatry 52 (2002) 68-70
56. Simon T.J., Bearden C.E., Mc-Ginn D.M., et al. Visuospatial and numerical cognitive deficits in children with chromosome 22q11.2 deletion syndrome. Cortex 41 (2005) 145-155
57. Campbell L.E., Daly E., Toal F., et al. Brain and behaviour in children with 22q11.2 deletion syndrome: a volumetric and voxel-based morphometry MRI study. Brain 129 pt 5 (2006) 1218-1228
58. Eliez S., Schmitt J.E., White C.D., et al. Children and adolescents with velocardiofacial syndrome: a volumetric MRI study. Am J Psychiatry 157 (2000) 409-415
59. Kates W.R., Burnette C.P., Jabs E.W., et al. Regional cortical white matter reductions in velocardiofacial syndrome: a volumetric MRI analysis. Biol Psychiatry 49 (2001) 677-684
60. Eliez S., Blasey C.M., Menon V., et al. Functional brain imaging study of mathematical reasoning abilities in velocardiofacial syndrome (del22q11.2). Genet Med 3 (2001) 49-55
61. Gothelf D, Hoeft F, Hinard C, et al. Abnormal cortical activation during response inhibition in 22q11.2 deletion syndrome. Hum Brain Mapp 2007, in press.
62. Bish J.P., Ferrante S.M., McDonald-McGinn D., et al. Maladaptive conflict monitoring as evidence for executive dysfunction in children with chromosome 22q11.2 deletion syndrome. Dev Sci 8 (2005) 36-43
63. Debbane M., Glaser B., David M.K., et al. Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: neuropsychological and behavioral implications. Schizophr Res 84 (2006) 187-193
64. Poulton R., Caspi A., Moffitt T.E., et al. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 57 (2000) 1053-1058
65. Niemi L.T., Suvisaari J.M., Tuulio-Henriksson A., et al. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res 60 (2003) 239-258
66. Gothelf D., Michaelovsky E., Frisch A., et al. Association of the low-activity COMT 158 Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int J Neuropsychopharmacol 31 (2006) 1-8
67. Egan M.F., Goldberg T.E., Kolachana B.S., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98 (2001) 6917-6922
68. Mattay V.S., Goldberg T.E., Fera F., et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 100 (2003) 6186-6191
69. Goldman-Rakic P.S., Muly III E.C., and Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31 (2000) 295-301
70. Zahrt J., Taylor J.R., Mathew R.G., et al. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17 (1997) 8528-8535
71. Cai J.X., and Arnsten A.F. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther 283 (1997) 183-189
72. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-57
73. Bearden C.E., Jawad A.F., Lynch D.R., et al. Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome. Am J Psychiatry 161 (2004) 1700-1702
74. Glaser B., Debbane M., Hinard C., et al. No evidence for an effect of COMT Val158Met genotype on executive function in patients with 22q11 deletion syndrome. Am J Psychiatry 163 (2006) 537-539
75. Bender H.U., Almashanu S., Steel G., et al. Functional consequences of PRODH missense mutations. Am J Hum Genet 76 (2005) 409-420
76. Paterlini M., Zakharenko S.S., Lai W.S., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8 (2005) 1586-1594
77. Liu H., Heath S.C., Sobin C., et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci U S A 99 (2002) 3717-3722
78. Raux G., Bumsel E., Hecketsweiler B., et al. Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome. Hum Mol Genet 16 (2007) 83-91
79. McGlashan T.H., Zipursky R.B., Perkins D., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163 (2006) 790-799
80. McGorry P.D., Yung A.R., Phillips L.J., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59 (2002) 921-928
81. Thomas L.E., and Woods S.W. The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment. Child Adolesc Psychiatr Clin N Am 15 (2006) 109-133
82. Gothelf D., Frisch A., Munitz H., et al. Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophr Res 35 (1999) 105-112
83. Graf W.D., Unis A.S., Yates C.M., et al. Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 57 (2001) 410-416
84. O'Hanlon J.F., Ritchie R.C., Smith E.A., et al. Replacement of antipsychotic and antiepileptic medication by L-alpha-methyldopa in a woman with velocardiofacial syndrome. Int Clin Psychopharmacol 18 (2003) 117-119
85. DuBois D.L., Holloway B.E., Valentine J.C., et al. Effectiveness of mentoring programs for youth: a meta-analytic review. Am J Community Psychol 30 (2002) 157-197
86. Shprintzen R.J., Goldberg R., Golding-Kushner K.J., et al. Late-onset psychosis in the velo-cardio-facial syndrome. Am J Med Genet 42 (1992) 141-142
87. Pulver A.E., Nestadt G., Goldberg R., et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis 182 (1994) 476-478